Overview

To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To demonstrate the relative bioavailability of Divalproex Sodium 500 mg delayed release tablets under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Valproic Acid